Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia
SummaryClinical management of chronic lymphocytic leukaemia (CLL) in patients aged ≥80 years is based on limited evidence due to the lack of published information. Therefore, we analysed CLL patients aged ≥80 years using data from seven phase III clinical trials of the German CLL Study Group. Among 3552 participants, 152 were ≥80 years old at initiation of first‐line st udy treatment. Median age was 82 years (range 80–90). Concomitant diseases were present in 99% of the patients, with a median cumulative illness rating scale score of 8 (0–18). Chemoimmunotherapy with chlorambucil‐obinutuzumab (CLB‐OB) or chlorambucil‐rituximab (CLB‐R) was administered to 61 (40%) and 56 (37%) patients. The remaining patients received CLB (n = 19) or fludarabine (F,n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2) or bendamustine/rituximab (BR, n = 3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%. Overall response rate was 77% with 13% complete remissions. Median progression‐free survival and treatment‐free survival were 17·2 and 32·3 months, respectively. Median overall survival was 48·3 months; adverse even ts (22%) and progressive CLL (16·4%) were the most frequent causes of death. These findings suggest that anti‐leukaemic treatment including chemoimmunotherapy is feasible and efficacious in ≥80‐year‐old CLL patients. However, this group of patients lives for a shorter time than age‐matche d control...
Source: British Journal of Haematology - Category: Hematology Authors: Othman Al ‐Sawaf,
Jasmin Bahlo,
Sandra Robrecht,
Kirsten Fischer,
Carmen D. Herling,
Manuela Hoechstetter,
Anna‐Maria Fink,
Julia Tresckow,
Petra Langerbeins,
Paula Cramer,
Stephan Stilgenbauer,
Clemens M. Wendtner,
Barbara Eichhorst,
Mic Tags: Research Paper Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Germany Health | Hematology | Leukemia | Rituxan | Study | Treanda | UK Health